Horizon Technology Finance Corp: directors' dealings · United States · SEC (Form 4)

About Horizon Technology Finance Corp

Horizon Technology Finance Corp. is a U.S.-listed specialty finance company trading on the NASDAQ under the ticker HRZN. The company was organized as a Delaware corporation on March 16, 2010, and operates as a non-diversified, externally managed business development company (BDC). Its operating footprint is centered in Farmington, Connecticut, with an additional presence in California, underscoring a U.S.-focused platform built to serve the domestic venture and growth financing market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1487428/000143774926006636/R12.htm?utm_source=openai)) Horizon’s core business is providing secured loans to venture capital-backed and private equity-backed companies, as well as to publicly traded growth businesses in targeted industries. Historically, its lending focus has concentrated on technology, life sciences, healthcare, healthcare services, and sustainability-related businesses. In practical terms, Horizon is a specialized credit investor that seeks income through structured debt investments and, in some cases, equity-linked upside through warrant positions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1487428/000143774925017203/ex_818593.htm?utm_source=openai)) From a competitive standpoint, Horizon occupies a niche within the U.S. financial sector: venture lending and specialty finance. Its competitive edge comes from sector specialization, underwriting discipline in asset-backed or secured structures, and close relationships with venture capital ecosystems. That specialization differentiates it from broad-based lenders, but it also means the company is more exposed to credit risk, valuation swings in its portfolio companies, and the capital-markets cycle affecting innovation-driven businesses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1487428/000143774925017203/ex_818593.htm?utm_source=openai)) Recent developments highlight both portfolio performance and corporate activity. In its March 2026 announcement of fourth-quarter and full-year 2025 results, the company reported a total investment portfolio of $647.2 million, net asset value of $318.5 million, or $6.98 per share, and an annualized debt-investment yield of 14.3% for the fourth quarter of 2025. Horizon also disclosed $154 million of committed backlog at year-end. In addition, the company announced in 2026 that a merger involving Monroe Capital Corporation was moving forward, with HRZN expected to remain the surviving publicly traded entity on the NASDAQ. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1512931/000143774926006801/hrzn20260303c_425.htm?utm_source=openai)) For French-speaking investors, HRZN is best viewed as a U.S. listed income-oriented specialty finance stock, tied to the financing of technology and healthcare growth companies, with a yield-driven profile that is highly sensitive to credit quality and the U.S. interest-rate environment.